Back HIV/AIDS

HIV / AIDS

UNAIDS and WHO Highlight Fast-Track Efforts to Expand HIV Prevention and Treatment

In advance of World AIDS Day, UNAIDS and the World Health Organization (WHO) released new reports describing successful local efforts to reduce new HIV infections and get more people living with HIV on effective treatment. The global World AIDS Day theme for 2015 is the Fast-Track to ending the AIDS epidemic by 2030 as part of the United Nations Sustainable Development Goals.With progress to date exceeding expectations, world leaders are now calling for accelerated efforts to achieve more ambitious goals.

alt

France Approves Truvada for HIV Pre-exposure Prophylaxis

In a historic move, France has become the first country outside the U.S., and the first country with a centrally organized, reimbursable health system, to approve no-expense pre-exposure prophylaxis (PrEP) for people who need it. The French Minister of Health, Marisol Touraine, announced on November 24 today that PrEP would be available starting in mid-December, and reimbursable through the French health system from the beginning of January.

alt

Widely Used Anti-Alcoholism Drug Wakes Up Dormant HIV-Infected Cells

An Australian research team has found that disulfiram, a long-established and safe drug used primarily as a treatment for alcohol dependency (well-known under its brand name Antabuse) can "wake up" quiescent HIV-infected reservoir cells and thus be used as the first stage of a hypothetical cure for HIV. The research was reported in the November 16 online edition of The Lancet HIV.

alt

Genvoya Pill with Tenofovir Alafenamide Added to Recommended HIV Regimens

The Department of Health and Human (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents has added the recently approved Genvoya single-tablet regimen containing elvitegravir and the new tenofovir alafenamide to its list of recommended regimens for initial HIV treatment.

alt

EACS 2015: Barcelona Clinic Study Counts How Many Gay Men Might Benefit from PrEP

A study from the Barcelona Checkpoint gay men’s HIV clinic, presented at the recent 15th European AIDS Conference, has found a strong and consistent relationship between the annual HIV infection rate (incidence) of different categories of clinic users and the particular combination of risk factors they self-report. The primary intention behind this study was to estimate what proportion of clinic users might benefit from HIV pre-exposure prophylaxis (PrEP). In doing the exercise, however, the clinic also managed to establish interesting new estimates for the relative contribution to HIV risk of condomless sex, sexually transmitted infections, high sex partner numbers, and sexual role.

alt

EACS 2015: Dual Therapy with Protease Inhibitors and Lamivudine Suppresses HIV

Dual antiretroviral regimens consisting of only a boosted HIV protease inhibitor (lopinavir/ritonavir or atazanavir) and a single inexpensive and well-tolerated NRTI may be enough to achieve and maintain HIV suppression in a most patients starting antiretroviral therapy (ART) for the first time or switching from a standard triple regimen, according to a pair of studies presented at the EACS 15th European AIDS Conference last month in Barcelona.

alt

How Do We Maximize HIV Treatment Access? IAPAC Care Continuum Guidelines Make Recommendations

IAPAC, the International Association of Practitioners in AIDS Care, has issued a set of guidelines that aims to establish a common set of best practices to ensure that as many people living with HIV as possible are diagnosed, cared for, receive treatment, and achieve undetectable viral loads.

alt